comparemela.com

Latest Breaking News On - Ascendis pharmaas company profile - Page 1 : comparemela.com

Seven Eight Capital LP Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Seven Eight Capital LP purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,636 shares of the biotechnology company’s stock, valued at approximately $2,347,000. A number of […]

Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Hold at StockNews com

StockNews.com upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) from a sell rating to a hold rating in a research report released on Thursday. A number of other equities research analysts have also commented on the stock. Morgan Stanley upped their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 […]

Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by StockNews com

StockNews.com upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) from a sell rating to a hold rating in a report released on Thursday. ASND has been the subject of several other reports. Wedbush raised their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in […]

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $140 00 by Analysts at Morgan Stanley

Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $140 00 by Analysts at Morgan Stanley
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of Moderate Buy from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.